Liver health is wealth – love your liver!

Liver health is wealth – love your liver!

We are delighted to invite you to our exciting evening event on Monday, 21 October 2024, at 6pm.

Liver disease is recognised as one of the top three causes of premature death in the UK. Held at our centre in Weybridge, Surrey, Professor Aftab Ala, an internationally recognised consultant gastroenterologist and hepatologist, will share key insights into early screening using onsite FibroScan, a tool that instantly detects and quantifies liver stiffness (or damage) and fatty liver.

We will also discuss the risk factors for liver disease and the management pathways for screening and treatment. Additionally, the benefits of early intervention and treatment will be highlighted.

Following the presentations, you will have the opportunity to tour our state-of-the-art facility and engage with our team to learn more about our innovative services, cutting-edge technology, and the potential benefits for your patients.

About our speaker

Professor Aftab Ala

Professor Aftab Ala is an internationally recognised consultant gastroenterologist and hepatologist with 30 years of NHS experience and 18 years as a Consultant Physician. He specialises in the assessment and management of liver and gastrointestinal diseases, using advanced tools like FibroScan, colonoscopy, and endoscopy. His NHS roles include positions at the Royal Surrey NHS Foundation Trust and King’s College Hospital.

Professor Ala holds an MBBS from Imperial College London, an MD (USMLE), and a PhD in hepatology from University College London. He completed specialist training at renowned institutions, including King’s and Royal Free Hospitals, and undertook advanced hepatology training in New York and Yale. He chairs the Gastroenterology and Hepatology Department at the University of Surrey and is the Chair of the British Association for the Study of the Liver (BASL) Rare Liver Disease Special Interest Group.

Professor Ala has authored over 200 peer-reviewed medical articles, supervises research students, and leads national and international research programs on liver disease, supported by NIHR and UKRI-MRC. He is actively involved in clinical trials, including pioneering gene therapy studies. He also holds key roles in scientific committees, NHS advisory boards, and professional liver associations, including AASLD and EASL.

View his full profile